作者@article {SpyratosPA4678 = {Spyratos, Dionisios g .和Tsiouprou Ioanna Tsartsianidou,瓦伦蒂娜Lampaki,索菲亚和Eleftheriadou Ellada Domvri, Kalliopi Kontakiotis,塞奥佐罗斯•},title ={实施PD-L1分析非小细胞肺癌患者中单个中心},体积= {54},number = {suppl 63}， location-id = {PA4678}， year = {2019}， doi = {10.1183/13993003.congress-2019。目前，癌症免疫疗法发展迅速，靶向程序性死亡-188bet官网地址1受体(PD-1)/PD配体-1 (PD- l1)通路的单克隆抗体已被批准用于非小细胞肺癌的治疗;然而，目前PD-L1分析在日常临床实践中的应用还缺乏证据。为此，我们在肺癌肿瘤科进行了一项回顾性观察研究。符合条件的患者为2017年4月至2018年12月在我科接受治疗的成年男女非小细胞肺癌患者。共123例患者进行了PD-L1表达的免疫组化检测22C3。123例患者中男性108例(87.8%)，平均年龄67.5岁9.3岁。诊断为鳞状细胞癌52例(42.3%)，腺癌63例(51.2%)，NOS、腺鳞癌和大细胞癌8例。123例标本中，4例不符合PD-L1免疫组化分析(\<100个恶性细胞/光场)。67例(54.5\%)PD-L1 TPS评分<1\%，20例(16\%)PD-L1 TPS评分>=50\%。 Also 41 patients (33.3\%) were treated with anti-PD-1 drugs (14 as first line, 19 as second and 8 as third). Eighteen of the patients who were treated with anti-PD-1 drugs were initially staged as IVA (43.9\%) and 7 as IVB (17.1\%). 14 out of 31 patients (20.4\%) had disease control (8 SD and 6 PR/CR).In this retrospective analysis we found that the percentage of patients with PD-L1 expression >=50\% was 16\% which is much lower than it was usually noticed in clinical trials. This could be probably attributed to the high percentage of patients with early or locally advanced tumors who were included.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4678.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/54/suppl_63/PA4678}, eprint = {//www.qdcxjkg.com/content}, journal = {European Respiratory Journal} }